0001005201-19-000005.txt : 20190207 0001005201-19-000005.hdr.sgml : 20190207 20190207160619 ACCESSION NUMBER: 0001005201-19-000005 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190206 FILED AS OF DATE: 20190207 DATE AS OF CHANGE: 20190207 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Peisert Daniel A. CENTRAL INDEX KEY: 0001758376 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-13111 FILM NUMBER: 19575234 MAIL ADDRESS: STREET 1: C/O ASSERTIO THERAPEUTICS, INC. STREET 2: 100 SOUTH SAUNDERS ROAD, SUITE 300 CITY: LAKE FOREST STATE: IL ZIP: 60045 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Assertio Therapeutics, Inc CENTRAL INDEX KEY: 0001005201 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943229046 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 100 SOUTH SAUNDERS RD STREET 2: SUITE 300 CITY: LAKE FOREST STATE: IL ZIP: 60045 BUSINESS PHONE: (224) 419-7106 MAIL ADDRESS: STREET 1: 100 SOUTH SAUNDERS RD STREET 2: SUITE 300 CITY: LAKE FOREST STATE: IL ZIP: 60045 FORMER COMPANY: FORMER CONFORMED NAME: DEPOMED INC DATE OF NAME CHANGE: 19970408 4 1 wf-form4_154957356263594.xml FORM 4 X0306 4 2019-02-06 0 0001005201 Assertio Therapeutics, Inc ASRT 0001758376 Peisert Daniel A. ASSERTIO THERAPEUTICS, INC. 100 SOUTH SAUNDERS ROAD, SUITE 300 LAKE FOREST IL 60045 0 1 0 0 SVP and CFO Common Stock 2019-02-06 4 M 0 6700 0 A 17675 D Common Stock 2019-02-06 4 F 0 2319 4.48 D 15356 D Restricted Stock Units 2019-02-06 4 M 0 6700 0 D 2021-02-06 Common Stock 6700.0 13400 D Represents shares of common stock withheld for payment of taxes upon the vesting of restricted stock units. Each restricted stock unit represents the contingent right to receive one share of common stock. This transaction represents the settlement of vested restricted stock units in shares of common stock. These restricted stock units are scheduled to vest 33.33% on February 6, 2019, 33.33% on February 6, 2020 and 33.33% on February 6, 2021. The derivative securities were granted to the reporting person, and were not sold to the reporting person. As such, the reporting person did not pay any consideration for the derivative securities. /s/ Erin R. McQuade, attorney in fact 2019-02-07